Merck and Co Archives -

Merck & Co has announced interim data from its pivotal Phase 3 KEYNOTE-564 trial evaluating immunotherapy Keytruda for

Merck’s Keytruda demonstrates adjuvant use in kidney cancer

https://pharmaphorum.com/news/mercks-keytruda/

Just a few weeks ago Merck & Co was lamenting a failed trial for Keytruda in triple-negative breast

Study resurrects Merck’s hopes for Keytruda in breast cancer

https://pharmaphorum.com/news/study-resurrects-mercks-hopes-for-keytruda-in-breast-cancer/

The FDA has approved a new triple-drug antibiotic from Merck & Co, but the company and regulator have

Merck gets FDA nod for new antibiotic, but says use with care

https://pharmaphorum.com/news/merck-gets-fda-nod-for-new-antibiotic-but-says-use-with-care/

Merck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals

Merck claims a brace of head and neck cancer approvals

https://pharmaphorum.com/news/merck-claims-a-brace-of-head-and-neck-cancer-approvals/

Merck and Co